Legendary rock band KISS is embarking on their final tour, half a century after they got started. Ahead of their final show in LA, Gene Simmons sat down with FOX 11's Christine Devine.
"The only reason we wanted to do the Bowl is because the Beatles did it," front man Gene Simmons said.
Meeting with FOX 11 for a sit-down interview, Simmons excitedly shared what LA fans can expect Friday at the famed outdoor concert venue. He says, miraculously, the city approved all of their demands for pyrotechnics, so tied to a KISS concert. At the famed Whisky a Go Go on the Sunset Strip, Simmons talked about why the band's touring days are coming to an end. He said KISS is "the hardest working band." That, in his seven-inch boots and forty pounds of wardrobe, "it's physically draining".fans on the band's very last shows. It all ends Dec. 2 at Madison Square Garden where the band launched in New York in 1973.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Cold Halloween is last celebration before Daylight Saving Time endsTaj Simmons is a multimedia journalist who joined WRTV in August 2023.
Read more »
A landmark gene-editing treatment for sickle cell disease moves closer to realityAdvisers to the Food and Drug Administration meet Tuesday to review the first treatment of human disease using the gene-editing technique CRISPR. The agency has a December deadline to make a decision.
Read more »
A landmark gene-editing treatment for sickle cell disease moves closer to realityAdvisers to the Food and Drug Administration meet Tuesday to review the first treatment of human disease using the gene-editing technique CRISPR. The agency has a December deadline to make a decision.
Read more »
FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell AnemiaNearly all patients treated so far have been relieved of the blood-clogging crises of the disease.
Read more »
Sarepta Stock Sinks on Mixed Gene Therapy ResultsIn a gene therapy study for patients with Duchenne muscular dystrophy, the primary endpoint was not met.
Read more »
Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goalCompany plans to seek label expansion for Duchenne muscular dystrophy treatment
Read more »